GlassScriptPhysician profile
Philip Marc Wilmoth
NPI 1427011360
$1,510.47
in general payments reported to CMS, 2019-2025
19 companies · $91.26 in 2025
The $91.26 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $305 · 2020: $46.21 · 2021: $121 · 2022: $285 · 2023: $391 · 2024: $270 · 2025: $91.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $753.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $753.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $263.09 | 2022-2025 | Tyrvaya, Ryzumvi |
| Novartis Pharmaceuticals Corporation | $241.88 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $189.66 | 2019-2025 | Cequa |
| Bausch & Lomb Americas INC. | $147.28 | 2023-2025 | Infuse, Biotrue One Day, Miebo |
| Johnson & Johnson Vision Care, INC. | $140.09 | 2019-2024 | Acuvue |
| Abbvie INC. | $88.01 | 2022-2023 | Vuity, Lumigan, Alphagan P |
| Alcon Vision LLC | $65.32 | 2022-2024 | Total30, Simbrinza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $60.62 | 2019 | |
| Dompe US, INC. | $52.66 | 2022-2024 | Oxervate |
| Shire North American Group INC | $41.91 | 2019 | |
| Mallinckrodt Enterprises LLC | $33.74 | 2019 | |
| Biotissue Holdings INC. | $31.47 | 2019-2022 | |
| Allergan, INC. | $30.75 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $29.61 | 2021-2024 | Acthar |
| Coopervision INC. | $29.19 | 2019-2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $19.05 | 2019 | |
| Kala Pharmaceuticals, INC. | $17.95 | 2021 | |
| Harrow Eye, LLC | $15.55 | 2024 | Vevye |
| Spark Therapeutics, INC. | $12.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Wilmoth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.